Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LAP3 | P28838 | 4/20 | 0.49 |
| ▸ | ANPEP | P15144 | 2/20 | 0.49 |
| ▸ | RNPEP | Q9H4A4 | 2/20 | 0.49 |
| ▸ | DNPEP | Q9ULA0 | 2/20 | 0.49 |
| ▸ | LMNA | P02545 | 1/20 | 0.44 |
| ▸ | PKM | P14618 | 1/20 | 0.44 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.43 |
| ▸ | NPC1 | O15118 | 1/20 | 0.40 |
| ▸ | RAB9A | P51151 | 1/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.40 |
| ▸ | MMP8 | P22894 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4071248 | 0.90 | CYP3A4 (0.50) | LAP3ANPEPRNPEPDNPEPMMP8 | |
| SCHEMBL6832227 | 0.79 | IL1RN (0.39) | ANPEPRNPEPDNPEP | |
| SCHEMBL4066984 | 0.76 | LTA4H (0.47) | NPC1RAB9ASMN1; SMN2MMP8 | |
| SCHEMBL4039170 | 0.76 | HPGD (0.41) | LMNASMN1; SMN2MMP8 | |
| SCHEMBL4058890 | 0.75 | CCR1 (0.36) | LMNASMN1; SMN2MMP8 | |
| SCHEMBL4065205 | 0.74 | FFAR2 (0.37) | LMNAL3MBTL1 | |
| SCHEMBL3936972 | 0.74 | REN (0.47) | LMNAMMP8 | |
| SCHEMBL4040963 | 0.74 | REN (0.47) | LMNAMMP8 | |
| SCHEMBL4063347 | 0.74 | CCR1 (0.37) | ANPEP | |
| SCHEMBL4043492 | 0.73 | VNN1 (0.39) | LAP3ANPEPRNPEPDNPEPMMP8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20020198207-A1 | Novel Hexanoic acid derivatives | KATH JOHN CHARLES (US) | 2002-12-26 | — | — | US | disclosed |
| US-6403587-B1 | AUTOIMMUNE DISEASES, ACUTE AND CHRONIC INFLAMMATORY CONDITIONS, ALLERGIC CONDITIONS, INFECTION ASSOCIATED WITH INFLAMMATION, VIRAL, TRANSPLANTATION TISSUE REJECTION, ATHEROSCLEROSIS, RESTENOSIS, HIV INFECTIVITY, AND | PFIZER INC. | 2002-06-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020198207-A1 | Novel Hexanoic acid derivatives | HCAR3, HCAR1, FFAR1 | LAP3 3585/4885ANPEP 4623/4885RNPEP 3404/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.